We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

To Provide Sildenafil Therapy To Eligible Adult Patients With Pulmonary Arterial Hypertension For 112 Weeks

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00946114
First Posted: July 24, 2009
Last Update Posted: February 15, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Pfizer
Results First Submitted: March 29, 2010  
Study Type: Observational
Study Design: Time Perspective: Prospective
Condition: Pulmonary Hypertension
Intervention: Drug: sildenafil

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Sildenafil 60 mg Sildenafil 20 mg TID (3 times daily); eligible adult subjects with PAH (pulmonary arterial hypertension)
Sildenafil 240 mg Sildenafil 80 mg TID (3 times daily); subjects who completed study A1481142

Participant Flow:   Overall Study
    Sildenafil 60 mg   Sildenafil 240 mg
STARTED   20   12 
COMPLETED   12   10 
NOT COMPLETED   8   2 
Death                5                2 
Other                1                0 
Withdrawal by Subject                2                0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Sildenafil 60 mg Sildenafil 20 mg TID (3 times daily); eligible adult subjects with PAH (pulmonary arterial hypertension)
Sildenafil 240 mg Sildenafil 80 mg TID (3 times daily); subjects who completed study A1481142
Total Total of all reporting groups

Baseline Measures
   Sildenafil 60 mg   Sildenafil 240 mg   Total 
Overall Participants Analyzed 
[Units: Participants]
 20   12   32 
Age, Customized 
[Units: Participants]
     
18 - 44 years   10   6   16 
45 - 64 years   8   6   14 
>= 65 years   2   0   2 
Gender 
[Units: Participants]
     
Female   17   9   26 
Male   3   3   6 


  Outcome Measures

1.  Primary:   Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)   [ Time Frame: Baseline up to 116 Weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Pfizer ClinicalTrials.gov Call Center
Organization: Pfizer, Inc.
phone: 1-800-718-1021
e-mail: ClinicalTrials.gov_Inquiries@pfizer.com



Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00946114     History of Changes
Other Study ID Numbers: A1481242
First Submitted: July 22, 2009
First Posted: July 24, 2009
Results First Submitted: March 29, 2010
Results First Posted: April 16, 2010
Last Update Posted: February 15, 2013